|
2026
|
Invention
|
Production of recombinant viral vectors from plant hairy roots.
The present invention relates to... |
|
2025
|
Invention
|
Modified aav capsid with enhanced transduction efficiency. The invention relates to a modified AA... |
|
|
G/S
|
Pharmaceutical, veterinary and sanitary products for medical purposes, namely gene and cell thera... |
|
|
G/S
|
Pharmaceutical, veterinary and sanitary products for medical
purposes; chemical preparations for... |
|
|
G/S
|
Produits pharmaceutiques, vétérinaires et hygiéniques pour la médecine; préparations chimiques à ... |
|
|
Invention
|
Alternative barcoding method to assess transduction efficiency of aav vectors. The invention rela... |
|
|
Invention
|
Cns gene delivery using peripheral administration of aav vectors.
The present invention relates ... |
|
|
Invention
|
Methods and systems for imaging cells in culture. The invention relates to a method for character... |
|
|
Invention
|
Acid-alpha glucosidase variants and uses thereof.
The present invention relates to variants of a... |
|
2024
|
Invention
|
Hybrid regulatory elements.
The present invention relates to hybrid transcription regulatory ele... |
|
|
Invention
|
Methods for aav vector re-administration. The invention relates to a combination of a recombinant... |
|
|
Invention
|
Prediction of multiple aav properties by deep learning. The invention relates to a method impleme... |
|
|
Invention
|
Prediction of multiple aav properties by deep learning |
|
|
Invention
|
Fluidic system for producing extracellular vesicles and related method.
A fluidic system for pro... |
|
|
Invention
|
Novel mididystrophins |
|
|
Invention
|
Novel optimized utrophin micro-genes. The present invention concerns a micro-utrophin comprising ... |
|
|
Invention
|
Novel mididystrophins. The present invention concerns mididystrophins comprising at least the rod... |
|
|
Invention
|
N-terminal truncated glycogen debranching enzymes for the treatment of glycogen storage disease iii |
|
|
Invention
|
N-terminal truncated glycogen debranching enzymes for the treatment of glycogen storage disease i... |
|
|
Invention
|
Hybrid recombinant adeno-associated virus serotype between aav9 and aavrh74 with reduced liver tr... |
|
|
Invention
|
Lentiviral vector for dopamine synthesis. The invention relates to a lentiviral vector comprising... |
|
|
Invention
|
Machine learning method for phenotype prediction. The present invention relates to the generation... |
|
|
Invention
|
Induction of immune tolerance by aav vector comprising the combination of a liver detargeted caps... |
|
2023
|
Invention
|
Lsd1 inhibitor and prmt6 inhibitor for use in the treatment of a disease associated with gain-of-... |
|
|
Invention
|
Tissue imaging methods and systems. The invention relates to a method for predicting treatment ef... |
|
|
G/S
|
Produits pharmaceutiques, vétérinaires et hygiéniques; préparations chimiques à usage médical, ph... |
|
|
G/S
|
Pharmaceutical, veterinary products, namely gene and cell therapy products for the treatment of d... |
|
|
G/S
|
Pharmaceutical, veterinary and hygienic products; chemical
preparations for medical and pharmace... |
|
|
Invention
|
Hybrid aav vector enhancing transgene expression in the liver.
The invention relates to a hybrid... |
|
|
Invention
|
Hybrid aav vector enhancing transgene expression in the liver |
|
|
Invention
|
Hybrid aav vector enhancing transgene expression in the liver. The invention relates to a hybrid ... |
|
|
Invention
|
Immunotherapy of skeletal myopathies using anti-fap car-t cells.
The invention relates to an imm... |
|
|
Invention
|
Immunotherapy of skeletal myopathies using anti-fap car-t cells |
|
|
Invention
|
Immunotherapy of skeletal myopathies using anti-fap car-t cells. The invention relates to an immu... |
|
|
Invention
|
Cns gene delivery using peripheral administration of aav vectors. The present invention relates t... |
|
|
Invention
|
Treatment of hyperbilirubinemia.
The invention relates to a nucleic acid sequence useful in the ... |
|
|
Invention
|
N-terminal truncated gde for the treatment of glycogen storage disease iii. The present invention... |
|
|
Invention
|
Peptide-modified aav capsid with enhanced muscle transduction efficiency. The invention relates t... |
|
|
Invention
|
Use of bazedoxifene for increasing muscle survival. The invention relates to the use of bazedoxif... |
|
|
Invention
|
Polynucleotides encoding a human fkrp protein. The present invention concerns synthetic polynucle... |
|
2022
|
Invention
|
Hybrid promoters for gene expression in muscles and in the cns.
The present invention relates to... |
|
|
Invention
|
Use of bazedoxifene for increasing muscle survival.
The invention concerns the use of bazedoxife... |
|
2021
|
Invention
|
Lysosomal acid lipase variants and uses thereof.
The present invention relates to variants of ly... |
|
|
Invention
|
Enhancing utrophin expression in cell by inducing mutations within utrophin regulatory elements a... |
|
|
Invention
|
Peptide-modified aav capsid.
The invention relates to a peptide-modified AAV capsid with improve... |
|
|
Invention
|
C-terminal truncated gde for the treatment of glycogen storage disease iii.
The present inventio... |
|
|
Invention
|
A novel muscle-specific promoter.
The present invention concerns a novel short promoter characte... |
|
|
Invention
|
Treatment of dilated cardiomyopathies.
The invention relates to the treatment of dilated cardiom... |
|
2020
|
Invention
|
Combination of a proteasome inhibitor and a hdac inhibitor and its use for the treatment of genet... |
|
|
Invention
|
Precise integration using nuclease targeted idlv.
The present invention relates to an integratio... |
|
|
Invention
|
Gene therapy of fibroblast growth factor 23 related hypophosphatemic diseases.
The invention rel... |
|
2012
|
G/S
|
Biological and chemical products used in the pharmaceutical and life sciences field, namely, reag... |
|
|
G/S
|
Pharmaceutical preparations for medical purposes,
pharmaceutical or chemical products, chemical-... |
